3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
Volume: 33, Issue: 15_suppl, Pages: e16102 - e16102
Published: May 20, 2015
Abstract
e16102 Background: Ra-223, an alpha-emitting radiopharmaceutical, significantly improved overall survival and was well tolerated in ALSYMPCA (Parker, NEJM2013). Ra-223 long-term safety monitoring is essential to a complete safety profile. Here we report adverse events (AEs) from ALSYMPCA pts 3 y after last pt’s first injection (inj). Methods: All pts were to enter designated follow-up from 4 wk after each pt’s last inj to 3 y after first inj....
Paper Details
Title
3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
Published Date
May 20, 2015
Journal
Volume
33
Issue
15_suppl
Pages
e16102 - e16102
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History